Similar Search Results

Quality Regulation and Competition : Evidence from Pharmaceutical Markets

Atal, Juan Pablo; Cuesta, José Ignacio; Sæthre, Morten - National Bureau of Economic Research - 2022

Quality regulation attempts to ensure quality and foster competition by reducing vertical differentiation, but it may also have adverse effects on market structure. We study this trade-off in the context of pharmaceutical bioequivalence, which is the primary quality standard for generic drugs....

Persistent link: https://www.econbiz.de/10013361980

Competition in the Pharmaceutical Industry : How Do Quality Differences Shape Advertising Strategies?

de Frutos, Maria Angeles - 2016

We present a Hotelling model of price and advertising competition between prescription drugs that differ in quality …. We show that advertising intensities are strategic substitutes, with the better quality drugs being the ones that are … loyalty is endogenously determined by promotional effort. The model's main results on advertising and pricing strategies are …

Persistent link: https://www.econbiz.de/10012986489

Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany

Herr, Annika; Suppliet, Moritz - 2012

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to …

Persistent link: https://www.econbiz.de/10010308640

Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany

Herr, Annika; Suppliet, Moritz - Düsseldorf Institute for Competition Economics (DICE), … - 2012

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to …

Persistent link: https://www.econbiz.de/10010956760

Is It Possible to Have Cheaper Drugs and Preserve the Incentive to Innovate: Reforming the Drug Approval Process According to Market Principles

Sauer, Corinne; Sauer, Robert - Jerusalem Institute for Market Studies (JIMS) - 2005

This paper argues that drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process. Lack of competition in the drug approval process has led to exceedingly high drug development costs....

Persistent link: https://www.econbiz.de/10004995401

Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure

Magazzini, Laura; Pammolli, Fabio; Riccaboni, Massimo - Volkswirtschaftliche Fakultät, … - 2004

distinction seems to emerge. On the one hand, systems that rely on market-based competition in pharmaceuticals promote a clear …

Persistent link: https://www.econbiz.de/10005034975

Deregulating the Norwegian Pharmaceuticals Market - Consequences for Costs and Availability

Rudholm, Niklas - Handelns Utredningsinstitut (HUI Research) - 2007

The aim of this paper is to analyze the impact of the deregulation of the Norwegian pharmaceuticals market in 2001 on … pharmacies have not decreased as a consequence of the deregulation of the Norwegian pharmaceuticals market. The deregulation of …

Persistent link: https://www.econbiz.de/10005419304

Business concentration through the eyes of the HHI

Djolov, George - In: International Journal of Economic Sciences and Applied … 7 (2014) 2, pp. 105-127

This paper examines the understanding of business concentration through the Her findahl-Hirschman Index (HHI), by showing that this index is conceptually a model according to which this concentration is the consequence of a renewal process. This process is prompted by firms engaging in different...

Persistent link: https://www.econbiz.de/10011310271

Business concentration through the eyes of the HHI

Djolov, George - In: International Journal of Business and Economic Sciences … 7 (2014) 2, pp. 105-127

Persistent link: https://www.econbiz.de/10011200077

Hospital Market Structure and Cost Performance: A Case Study

Santerre, Rexford E.; Bennett, Dana C. - In: Eastern Economic Journal 18 (1992) 2, pp. 209-219

Prior research on the nonprice theory of hospital competition uses data prior to the mid-1980s when third party payers were insensitive to hospital prices. Moreover, existing studies fail to test this theory for the different types of hospital ownership. In response to these issues, this...

Persistent link: https://www.econbiz.de/10005641644